Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Bacon, B.R.
6129  Ergebnisse:
Personensuche X
?
1

Disparate access to treatment regimens in chronic hepatitis..:

Younossi, Z. M. ; Bacon, B. R. ; Dieterich, D. T....
Journal of Viral Hepatitis.  23 (2016)  6 - p. 447-454 , 2016
Link: https://doi.org/10.1111/..
 
?
2

Real‐world effectiveness for 12 weeks of ledipasvir–sofosbu..:

Tapper, E. B. ; Bacon, B. R. ; Curry, M. P....
Journal of Viral Hepatitis.  24 (2016)  1 - p. 22-27 , 2016
Link: https://doi.org/10.1111/..
 
?
3

Adherence to assigned dosing regimen and sustained virologi..:

Gordon, S. C. ; Yoshida, E. M. ; Lawitz, E. J....
Alimentary Pharmacology & Therapeutics.  38 (2013)  1 - p. 16-27 , 2013
Link: https://doi.org/10.1111/..
 
?
4

1430 SAFETY AND EFFICACY OF BOCEPREVIR/PEGINTERFERON/ RIBAV..:

Vierling, J.M. ; Zeuzem, S. ; Poordad, F....
Journal of Hepatology.  58 (2013)  - p. S576-S577 , 2013
Link: https://doi.org/10.1016/..
 
?
5

66 HIGH SUSTAINED VIRAL RESPONSE AT 12- AND 24-WEEK FOLLOW-..:

Manns, M. ; Vierling, J.M. ; Bacon, B.R....
Journal of Hepatology.  58 (2013)  - p. S30 , 2013
Link: https://doi.org/10.1016/..
 
?
6

791 VIROLOGIC RESPONSE RATES ARE SIMILAR IN PREVIOUSLY UNTR..:

Bacon, B.R. ; Poordad, F. ; Bronowicki, J.-P....
Journal of Hepatology.  58 (2013)  - p. S322-S323 , 2013
Link: https://doi.org/10.1016/..
 
?
7

428 ADHERENCE TO ASSIGNED DOSING REGIMEN AND SUSTAINED VIRO..:

Gordon, S.C. ; Lawitz, E.J. ; Bacon, B.R....
Journal of Hepatology.  54 (2011)  - p. S173-S174 , 2011
Link: https://doi.org/10.1016/..
 
?
8

12 IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIEN..:

Poordad, F. ; Bronowicki, J.-P. ; Gordon, S.C....
Journal of Hepatology.  54 (2011)  - p. S6 , 2011
Link: https://doi.org/10.1016/..
 
?
9

448 RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFE..:

Manns, M.P. ; Poordad, F. ; Bacon, B.R....
Journal of Hepatology.  54 (2011)  - p. S182-S183 , 2011
Link: https://doi.org/10.1016/..
 
?
10

2001 PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED S..:

Bacon, B.R. ; Shiffman, M.L. ; Lim, J.K....
Journal of Hepatology.  52 (2010)  - p. S463 , 2010
Link: https://doi.org/10.1016/..
 
?
11

Meta‐analysis: re‐treatment of genotype I hepatitis C nonre..:

Singal, A. G. ; Waljee, A. K. ; Shiffman, M...
Alimentary Pharmacology & Therapeutics.  32 (2010)  8 - p. 969-983 , 2010
Link: https://doi.org/10.1111/..
 
?
12

Clinical trial: randomized controlled study of zidovudine a..:

MASON, A. L. ; LINDOR, K. D. ; BACON, B. R....
Alimentary Pharmacology & Therapeutics.  28 (2008)  7 - p. 886-894 , 2008
Link: https://doi.org/10.1111/..
 
?
13

[648] CHARACTERISATION OF HCV GENOTYPE 2/3 PATIENTS WITHOUT..:

Shiftman, M.L. ; Minola, E. ; Barange, K....
Journal of Hepatology.  46 (2007)  - p. S245 , 2007
Link: https://doi.org/10.1016/..
 
?
14

Assessing evidence from clinical trials in chronic hepatiti..:

Bacon, B. R.
Journal of Viral Hepatitis.  13 (2006)  s1 - p. 1-5 , 2006
Link: https://doi.org/10.1111/..
 
?
15

111 Final results of a multi-center phase 1b, randomized, p..:

McHutchison, J.G. ; Bacon, B.R. ; Gordon, S.C....
Journal of Hepatology.  44 (2006)  - p. S49 , 2006
Link: https://doi.org/10.1016/..
 
1-15